Stifel Maintains Buy on Tandem Diabetes Care, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman maintains a Buy rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $37 to $40.
April 23, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Mathew Blackman maintains a Buy rating on Tandem Diabetes Care and raises the price target from $37 to $40.
The increase in price target by Stifel reflects a positive outlook on Tandem Diabetes Care's stock, likely due to strong company performance or market position. This analyst endorsement can boost investor confidence, potentially leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100